MarketPulse

generic drugs

3 articles
Investing.comInvesting.com··Nathan Reiff

Lilly's Double-Beat Widens GLP-1 Gap as Foundayo Pill Transforms Market

Eli Lilly beats Q1 earnings, raises $2B guidance, and wins FDA approval for Foundayo, the first unrestricted oral GLP-1, widening gap over Novo Nordisk.
LLYNVOFDA approvalweight loss medications
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Teva Pharmaceutical Faces Structural Challenges Amid Strategic Pivot

Teva Pharmaceutical faces margin compression in generic drugs, pivoting toward complex generics and original drug development. Limited financial flexibility creates elevated execution risk.
PFETEVAGLP-1 drugsdrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Esperion Secures Fifth Settlement with Generic Drug Maker Over NEXLETOL, NEXLIZET Patents

Esperion secures fifth settlement with generic drugmaker Alkem, extending market exclusivity for cholesterol drugs NEXLETOL and NEXLIZET through April 2040.
SDZNYESPRpatent settlementgeneric drugs